Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04771130 · ClinicalTrials.gov registry record · Phase 1
A Study of BGB-11417 in Participants With Myeloid Malignancies
A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by BeiGene.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT04771130: Recruiting Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by BeiGene.
NCT04771130 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by BeiGene. The registered enrollment target is 260 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04771130, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by BeiGene.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Posaconazole
- DRUG BGB-11417
Study Locations (20)
Victoria
- Monash Health - Clayton
- St Vincents Hospital Melbourne - Fitzroy
- Austin Health - Heidelberg
- The Alfred Hospital - Melbourne
New South Wales
- Concord Repatriation General Hospital - Concord
- St George Hospital - Kogarah
- Orange Health Hospital - Orange
Western Australia
- Fiona Stanley Hospital - Murdoch
- Linear Clinical Research - Nedlands
- One Clinical Research - Nedlands
Guangdong
- Guangdong Provincial Peoples Hospital - Guangzhou
- Nanfang Hospital of Southern Medical University - Guangzhou
California
- City of Hope National Medical Center - Duarte
Florida
- Tampa General Hospital - Tampa
Pennsylvania
- Upmc Hillman Cancer Center(Univ of Pittsburgh) - Pittsburgh
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2028-02-08 |
| Phase | Phase 1 |
What NCT04771130 shows while recruiting
NCT04771130 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (126% higher).
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Azacitidine is the first listed.
NCT04771130 names 20 study sites across 12 states, led by Victoria, New South Wales, Western Australia.
Frequently Asked Questions
What is clinical trial NCT04771130 about?
NCT04771130 is a clinical study titled "A Study of BGB-11417 in Participants With Myeloid Malignancies". The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
What is the current status of trial NCT04771130?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2021-05-24. Estimated completion is 2028-02-08.
What conditions does trial NCT04771130 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT04771130?
The interventions under investigation include: Azacitidine (DRUG), Posaconazole (DRUG), BGB-11417 (DRUG).
Who is sponsoring clinical trial NCT04771130?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04771130 being conducted?
This trial has 20 study locations across California, Florida, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04771130's enrollment target sits among peer trials
260 33rd of 306 higher than 274 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI